Breaking News, Collaborations & Alliances

CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development

Partnership combines CureVac’s mRNA technology with myNEO’s platform for discovery and selection of tumor antigens.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and myNEO N.V., a Belgium-based immunotherapy company, entered into a research and option agreement.    Both companies aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. myNEO will leverage its biological datasets and its integrated machine learning and bioinformatics platform to identify...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters